Tumor-associated macrophages in immune microenvironment of lung cancer

doi:10.3760/cma.j.issn.1673-422X.2014.11.010

Abstract

Abstract: With the research on tumor immunity and tumor immunosuppression development, immunotherapies for lung cancer has become a research hotspot. Tumor immune microenvironment plays an important role in tumor genesis, development and metastasis of lung cancer. Tumorassociated macrophages (TAMs) are the dominant leukocyte population found in immune microenvironment of lung cancer. The relationship between TAMs and lung cancer becomes clear with further research. TAMs may become the new target of lung cancer immunotherapy.

Key words: Lung neoplasms, Macrophages, Tumor microenvironment

DING Yi-Hui, ZHANG Kai, HU Yue, LIU Li. Tumor-associated macrophages in immune microenvironment of lung cancer[J]. Journal of International Oncology, 2014, 41(11): 830-833.

References

［1］ Siegel R, Ma J, Zou Z, et al. Cancer Statistics, 2014［J］. CA Cancer J Clin, 2014, 64(1): 929. ［2］ Schmieder A, Michel J, Schnhaar K, et al. Differentiation and gene expression profile of tumorassociated macrophages［J］. Semin Cancer Biol， 2012, 22(4):289297. ［3］ Shirabe K, Mano Y, Muto J, et al. Role of tumorassociated macrophages in the progression of hepatocellular carcinoma［J］. Surg Today， 2012, 42(1):17. ［4］ Wang XF, Wang HS, Zhang F, et al. Nodal promotes the generation of M2like macrophages and downregulates the expression of IL12［J］. Eur J Immunol， 2014， 44(1):173183. ［5］ Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment［J］. Trends Immunol, 2012, 33(3):119126. ［6］ Quatromoni JG, Eruslanov E. Tumorassociated macrophages: function, phenotype, and link to prognosis in human lung cancer［J］. Am J Transl Res, 2012, 4(4):376389. ［7］ Dasanu CA, Sethi N, Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer［J］. Expert Opin Biol Ther， 2012, 12(7):923937. ［8］ Chung FT, Lee KY, Wang CW, et al. Tumorassociated macrophages correlate with response to epidermal growth factor receptortyrosine kinase inhibitors in advanced nonsmall cell lung cancer［J］. Int J Cancer, 2012, 131(3):E227E235. ［9］ Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NYESO1［J］. N Engl J Med, 2008, 358(25):26982703. ［10］ Reck M. What future opportunities may immunooncology provide for improving the treatment of patients with lung cancer?［J］. Ann Oncol， 2012，23 Suppl 8:viii2834. ［11］ Brahmer JR. Harnessing the immune system for the treatment of nonsmallcell lung cancer［J］. J Clin Oncol, 2013, 31(8):10211028. ［12］ Shepherd FA, Douillard JY, Blumenschein GR Jr. Immunotherapy for nonsmall cell lung cancer: novel approaches to improve patient outcome［J］. J Thorac Oncol， 2011, 6(10):17631773. ［13］徐燕, 王孟昭. 非小细胞肺癌免疫治疗进展［J］. 中国肺癌杂志, 2014, 17(1): 3441. ［14］ Lievense LA, Bezemer K, Aerts JG, et al. Tumorassociated macrophages in thoracic malignancies［J］. Lung Cancer, 2013, 80(3):256262. ［15］ Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers［J］. J Transl Med， 2011， 9: 216. ［16］ Wang R, Zhang J, Chen S, et al. Tumorassociated macrophages provide a suitable microenvironment for nonsmall lung cancer invasion and progression［J］. Lung Cancer, 2011, 74(2):188196. ［17］ Zhang Y, Choksi S, Chen K, et al. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumorassociated macrophages［J］. Cell Res, 2013, 23(7):898914. ［18］ Zhang Y, Choksi S, Liu ZG. Butylated hydroxyanisole blocks the occurrence of tumor associated macrophages in tobacco smoke carcinogeninduced lung tumorigenesis［J］. Cancers (Basel), 2013， 5(4): 16431654. ［19］ Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin［J］. Cancer Cell, 2013, 23(2):249262. ［20］ Welsh TJ, Green RH, Richardson D, et al. Macrophage and mastcell invasion of tumor cell islets confers a marked survival advantage in nonsmallcell lung cancer［J］. J Clin Oncol, 2005, 23(35):89598967. ［21］ Ohri CM, Shikotra A, Green RH, et al. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival［J］. Eur Respir J, 2009, 33(1):118126. ［22］ Shao R. YKL40 acts as an angiogenic factor to promote tumor angiogenesis［J］. Front Physiol, 2013, 4(122):19. ［23］ Thm I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL40An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer［J］. Cancer, 2010, 116(17): 41144121. ［24］ Standiford TJ, Kuick R, Bhan U, et al. TGFβinduced IRAKM expression in tumorassociated macrophages regulates lung tumor growth［J］. Oncogene， 2011, 30(21):24752484. ［25］ Kühnemuth B, Mühlberg L, Schipper M, et al. CUX1 modulates polarization of tumorassociated macrophages by antagonizing NFκB signaling［J］. Oncogene， 2013， In press.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[5]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie. Research progress of myeloid-derived suppressor cells in tumor angiogenesis [J]. Journal of International Oncology, 2024, 51(1): 50-54.
[6]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[7]	Zhang Li, Xiang Zhuo, Wang Qiang, Bi Jingwang. Research progress of cytokine release syndrome related to CAR-T immunotherapy [J]. Journal of International Oncology, 2023, 50(6): 377-381.
[8]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[9]	Ding Hao, Ying Jintao, Fu Maoyong. Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(4): 231-235.
[10]	Cao Mengqing, Xu Zhiyong, Shi Yuting, Wang Kai. Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy [J]. Journal of International Oncology, 2023, 50(3): 169-173.
[11]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[12]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[13]	Zhu Yi, Chen Jian. Mechanism of hydrogen sulfide in tumorigenesis and development and its donor-mediated anti-tumor effects [J]. Journal of International Oncology, 2023, 50(12): 729-733.
[14]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[15]	Xie Lulu, Ding Jianghua. Progress of immunotherapy-based strategy in triple-negative breast cancer [J]. Journal of International Oncology, 2023, 50(11): 672-676.